Experimental and integrative analyses identify an ETS1 network downstream BCR-ABL in chronic myeloid leukemia (CML)

Chronic myeloid leukemia (CML) accounts for approximately 15% of the newly diagnosed cases of leukemia in adults (1). The BCR-ABL1 fusion gene resulting from the t (9;22) chromosomal translocation is expressed in all CML cells. It encodes the BCR-ABL protein, which is required for oncogenic transformation (2,3). BCR-ABL is a constitutively active tyrosine kinase that promotes the proliferation and survival of leukemic cells through several downstream well-known effectors such as RAS, MYC, and STAT (4 –6).

Source: Experimental Hematology - May 4, 2018 Category: Hematology Authors: Christophe Desterke, Maud Voldoire, Marie-Laure Bonnet, Nathalie Sorel, Sarah Pagliaro, Hind Rahban, Annelise Bennaceur Griscelli, Emilie Cayssials, Jean-Claude Chomel, Ali G Turhan Tags: Malignant Hematopoiesis Source Type: research